<p>CorMedix Inc. (NASDAQ:CRMD - 获取免费报告) 的股价在周四的午盘交易中上涨了 6.9%。该股最高交易价格为$13.32，最后交易价格为$13.23。在交易中成交了 1,565,066 股，较平均交易量 1,179,993 股增加了 33%。该股此前收盘价为$12.38。</p>
<h2>华尔街分析师观点</h2>
<p>CRMD 最近成为几份研究报告的主题。华尔街禅在 4 月 1 日的研究报告中将 CorMedix 的评级从 “卖出” 上调至 “持有”。D. Boral Capital 在 5 月 6 日的研究报告中重申了 “买入” 评级，并对 CorMedix 的股票设定了$15.00 的目标价。加拿大皇家银行在 3 月 26 日的研究报告中重新发布了 “跑赢大盘” 评级，并对 CorMedix 的股票设定了$12.00 的目标价。Leerink Partners 在 3 月 7 日的研究报告中将 CorMedix 的评级上调至 “强力买入”。最后，Needham &amp; Company LLC 在 5 月 7 日的报告中将 CorMedix 的目标价从$12.00 提高至$15.00，并给予该公司 “买入” 评级。一位股票研究分析师对该股给予了持有评级，六位分析师给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，平均目标价为$15.00。</p>
<p><strong>查看我们最新的 CorMedix 股票报告</strong></p>
<h2>CorMedix 股价上涨 6.5%</h2>
<p>该公司的 50 日移动平均线为$9.52，200 日移动平均线为$9.88。该公司的市值为$893.93 百万，市盈率为-16.27，贝塔值为 1.54。</p>
<p>CorMedix (NASDAQ:CRMD - 获取免费报告) 最近在 5 月 6 日发布了其财报。该公司报告本季度每股收益为$0.30，超出市场共识预期的$0.25，超出$0.05。该公司本季度的收入为$39.08 百万，而市场共识预期为$38.90 百万。在去年同期，该公司每股收益为 ($0.25)。股票分析师预测 CorMedix Inc.在当前财政年度将发布-0.32 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。SBI 证券有限公司在第一季度将其在 CorMedix 的持股增加了 699.7%。SBI 证券有限公司目前拥有 8,685 股该公司的股票，价值$54,000，此前在上个季度又购买了 7,599 股。Janney Montgomery Scott LLC 在第四季度购买了 CorMedix 的新头寸，价值$81,000。Essex Financial Services Inc.在第一季度购买了价值约$63,000 的 CorMedix 新股份。EntryPoint Capital LLC 在第一季度获得了价值约$66,000 的 CorMedix 新股份。最后，Captrust Financial Advisors 在第四季度购买了价值约$90,000 的 CorMedix 新头寸。机构投资者持有该公司 34.18% 的股票。</p>
<h2>关于 CorMedix</h2>
<p>(获取免费报告)</p>
<p>CorMedix Inc 是一家生物制药公司，专注于开发和商业化用于预防和治疗美国感染性和炎症性疾病的治疗产品。其主要产品候选是 DefenCath，一种抗菌导管锁定溶液，旨在减少肾衰竭成人患者导管相关血流感染的发生率。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票而非 CorMedix</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Meta 是否在 Libra 失败多年后策划稳定币的回归？</li>
<li>为什么投资高收益股息股票？</li>
<li>白银的期权火热：交易者是否在押注突破？</li>
<li>深入了解买卖差价</li>
<li>AT&amp;T：这家电信巨头是买入还是卖出你的投资组合？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 CorMedix 吗？</h2>
<p>在你考虑投资 CorMedix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 CorMedix 并不在名单上。</p>
<p>虽然 CorMedix 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRMD

<p>CorMedix Inc.（纳斯达克代码：CRMD）的股价上涨了 6.9%，达到 13.23 美元，交易量增加了 33%。分析师的评级各不相同，其中一位持有评级，六位买入评级和一位强烈买入评级。平均目标价为 15.00 美元。该公司报告每股收益为 0.30 美元，超出预期，收入为 3908 万美元。机构投资者持有 34.18% 的股份。CorMedix 专注于开发针对传染病的治疗产品，其主要产品为 DefenCath</p>

<p>CorMedix Inc. (NASDAQ:CRMD - Get Free Report)'s share price traded up 6.9% during mid-day trading on Thursday . The stock traded as high as $13.32 and last traded at $13.23. 1,565,066 shares were traded during trading, an increase of 33% from the average session volume of 1,179,993 shares. The stock had previously closed at $12.38.</p>
<div class="lb-trans"><p>CorMedix Inc. (NASDAQ:CRMD - 获取免费报告) 的股价在周四的午盘交易中上涨了 6.9%。该股最高交易价格为$13.32，最后交易价格为$13.23。在交易中成交了 1,565,066 股，较平均交易量 1,179,993 股增加了 33%。该股此前收盘价为$12.38。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>CRMD has been the subject of several recent research reports. Wall Street Zen raised CorMedix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a &#34;buy&#34; rating and issued a $15.00 price objective on shares of CorMedix in a research note on Tuesday, May 6th. Royal Bank of Canada reissued an &#34;outperform&#34; rating and set a $12.00 target price on shares of CorMedix in a research report on Wednesday, March 26th. Leerink Partnrs raised CorMedix to a &#34;strong-buy&#34; rating in a research report on Friday, March 7th. Finally, Needham &amp; Company LLC increased their price objective on CorMedix from $12.00 to $15.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Buy&#34; and an average price target of $15.00.</p>
<div class="lb-trans"><p>CRMD 最近成为几份研究报告的主题。华尔街禅在 4 月 1 日的研究报告中将 CorMedix 的评级从 “卖出” 上调至 “持有”。D. Boral Capital 在 5 月 6 日的研究报告中重申了 “买入” 评级，并对 CorMedix 的股票设定了$15.00 的目标价。加拿大皇家银行在 3 月 26 日的研究报告中重新发布了 “跑赢大盘” 评级，并对 CorMedix 的股票设定了$12.00 的目标价。Leerink Partners 在 3 月 7 日的研究报告中将 CorMedix 的评级上调至 “强力买入”。最后，Needham &amp; Company LLC 在 5 月 7 日的报告中将 CorMedix 的目标价从$12.00 提高至$15.00，并给予该公司 “买入” 评级。一位股票研究分析师对该股给予了持有评级，六位分析师给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “买入”，平均目标价为$15.00。</p>
</div><p><strong>View Our Latest Stock Report on CorMedix</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CorMedix 股票报告</strong></p>
</div><h2>CorMedix Stock Up 6.5%</h2>
<div class="lb-trans"><h2>CorMedix 股价上涨 6.5%</h2>
</div><p>The business has a 50-day moving average of $9.52 and a two-hundred day moving average of $9.88. The firm has a market capitalization of $893.93 million, a price-to-earnings ratio of -16.27 and a beta of 1.54.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为$9.52，200 日移动平均线为$9.88。该公司的市值为$893.93 百万，市盈率为-16.27，贝塔值为 1.54。</p>
</div><p>CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.25 by $0.05. The firm had revenue of $39.08 million during the quarter, compared to the consensus estimate of $38.90 million. During the same period last year, the business earned ($0.25) earnings per share. Equities analysts predict that CorMedix Inc. will post -0.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CorMedix (NASDAQ:CRMD - 获取免费报告) 最近在 5 月 6 日发布了其财报。该公司报告本季度每股收益为$0.30，超出市场共识预期的$0.25，超出$0.05。该公司本季度的收入为$39.08 百万，而市场共识预期为$38.90 百万。在去年同期，该公司每股收益为 ($0.25)。股票分析师预测 CorMedix Inc.在当前财政年度将发布-0.32 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. raised its holdings in shares of CorMedix by 699.7% in the 1st quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company's stock worth $54,000 after buying an additional 7,599 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of CorMedix during the fourth quarter valued at $81,000. Essex Financial Services Inc. bought a new stake in shares of CorMedix in the 1st quarter worth about $63,000. EntryPoint Capital LLC acquired a new stake in shares of CorMedix during the 1st quarter worth about $66,000. Finally, Captrust Financial Advisors bought a new position in CorMedix during the 4th quarter valued at about $90,000. Institutional investors own 34.18% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。SBI 证券有限公司在第一季度将其在 CorMedix 的持股增加了 699.7%。SBI 证券有限公司目前拥有 8,685 股该公司的股票，价值$54,000，此前在上个季度又购买了 7,599 股。Janney Montgomery Scott LLC 在第四季度购买了 CorMedix 的新头寸，价值$81,000。Essex Financial Services Inc.在第一季度购买了价值约$63,000 的 CorMedix 新股份。EntryPoint Capital LLC 在第一季度获得了价值约$66,000 的 CorMedix 新股份。最后，Captrust Financial Advisors 在第四季度购买了价值约$90,000 的 CorMedix 新头寸。机构投资者持有该公司 34.18% 的股票。</p>
</div><h2>About CorMedix</h2>
<div class="lb-trans"><h2>关于 CorMedix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.</p>
<div class="lb-trans"><p>CorMedix Inc 是一家生物制药公司，专注于开发和商业化用于预防和治疗美国感染性和炎症性疾病的治疗产品。其主要产品候选是 DefenCath，一种抗菌导管锁定溶液，旨在减少肾衰竭成人患者导管相关血流感染的发生率。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than CorMedix</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop?</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Silver's Options Sizzle: Are Traders Betting on a Breakout?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>AT&amp;T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 CorMedix</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Meta 是否在 Libra 失败多年后策划稳定币的回归？</li>
<li>为什么投资高收益股息股票？</li>
<li>白银的期权火热：交易者是否在押注突破？</li>
<li>深入了解买卖差价</li>
<li>AT&amp;T：这家电信巨头是买入还是卖出你的投资组合？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CorMedix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 CorMedix 吗？</h2>
</div><p>Before you consider CorMedix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 CorMedix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 CorMedix 并不在名单上。</p>
</div><p>While CorMedix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CorMedix 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CorMedix (NASDAQ:CRMD) 股价上涨 6.9% - 现在是买入的好时机吗？